Cross country pharmaceutical regional pooled procurement mechanisms: a scoping review_Chinese Journal of Evidence-Based Medicine

Authors：

HE Yinqi , XIONG Yineng , FU Yihan , WANG Danning , CHEN Weilin ,  SUN Jing

School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, P. R. China;

Corresponding?author：

SUN Jing, Email: sunjing@sph.pumc.edu.cn

Keywords：

Medical products; Regional pooled procurement; Scoping review

DOI：

10.7507/1672-2531.202602051

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review and compare global pharmaceutical regional pooled procurement mechanisms, with the aim of generating evidence to inform decision-making in optimization of medicines regional pooled procurement. Methods Comprehensively search published literature about pharmaceutical regional pooled procurement mechanisms from the inception of each database to the end of 2025 from CNKI, Web of Science, PubMed, Embase and Scopus. Characteristics of the targeted mechanisms were extracted from the included literature. Supplementary information was obtained from official websites of the referenced pharmaceutical regional pooled procurement mechanisms, related international organizations and major media platforms. The compiled information was then categorized for comparative analysis. Results A total of 74 literature were included in the analysis, which identified 15 pharmaceutical regional pooled procurement mechanisms. Geographically, the literature predominantly focused on Europe (n=39) and the Americas (n=31). Among these, the Joint Procurement Agreement of the European Union (n=30) and the Revolving Fund of the Pan American Health Organization (n=26) were studied the most. All continents established pharmaceutical regional pooled procurement mechanisms. The majority of these mechanisms (n=10, 66.7%) remain operational. The scope of procured medical products ranged from essential medicines and vaccines to expensive novel medicines, which closely aligns with the regional economic development. To secure operation and management, most of these mechanisms levy an administrative fee on the member states. Conclusion To ensure the sustainability of the pharmaceutical regional pooled procurement, it is essential to foster stronger regional identity and solidarity, leverage economies of scale, ensure greater transparency, establish stable funding mechanisms, and strengthen technological capacity for accurate forecasting, monitoring and evaluation of the supply and demand.

Citation： HE Yinqi, XIONG Yineng, FU Yihan, WANG Danning, CHEN Weilin, SUN Jing. Cross country pharmaceutical regional pooled procurement mechanisms: a scoping review. Chinese Journal of Evidence-Based Medicine, 2026, 26(9): 1020-1027. doi: 10.7507/1672-2531.202602051 Copy

1.	Wang LX, Zahur NB. Procurement institutions and essential drug supply in low and middle-income countries[J]. J Health Econ, 2025, 101: 102996.
2.	焦慧霖, 湯少梁, 毛曉艷, 等. 藥品集中帶量采購政策背景下慢性病患者藥品福利感知的變化及對其健康水平的影響研究[J]. 中國衛生經濟, 2025, 44(3): 30-36.
3.	王朝輝, 蔣昌松, 聶曼玲, 等. 國家組織藥品集中采購政策對抗乳腺癌藥品使用的影響研究[J]. 衛生經濟研究, 2025, 42(4): 37-41.
4.	Blau J, Hoestlandt C, D Clark A, et al. Strengthening national decision-making on immunization by building capacity for economic evaluation: implementing ProVac in Europe[J]. Vaccine, 2015, 33(Suppl 1): A34-A39.
5.	Le Gargasson JB, Breugelmans JG, Mibulumukini B, et al. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC)[J]. Vaccine, 2013, 31(15): 1886-1891.
6.	Matiru R, Ryan T. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management[J]. Bull World Health Organ, 2007, 85(5): 348-353.
7.	Parmaksiz K, Asingizwe D, Gichohi AK, et al. Towards regional access to medicines: the development of the East African Community pooled procurement mechanism[J]. J Pharm Policy Pract, 2024, 17(1): 2390653.
8.	Azzopardi Muscat N. The European added value of health system cooperation to ensure access to innovative medicines and technologies[J]. J Malta College Pharm Pract, 2017, 23: 4-6.
9.	Phan D. Access to immunization in middle-income countries: immunization agenda 2030 in depth review[Z]. Immunization Agenda, 2030. 2025.
10.	Pagliusi S, Che Y, Dong S. The art of partnerships for vaccines[J]. Vaccine, 2019, 37(40): 5909-5919.
11.	Azzopardi-Muscat N, Schroder-B?ck P, Brand H. The European Union Joint procurement agreement for cross-border health threats: what is the potential for this new mechanism of health system collaboration[J]. Health Econ Policy Law, 2017, 12(1): 43-59.
12.	劉晏利, 吳才志, 王浙, 等. JBI范圍綜述執行流程簡介[J]. 中國循證醫學雜志, 2024, 24(8): 986-992.
13.	Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review. Guidance for authors when choosing between a systematic or scoping review approach[J]. BMC Med Res Methodol, 2018, 18(1): 143.
14.	Parmaksiz K, Pisani E, Bal R, et al. A systematic review of pooled procurement of medicines and vaccines: identifying elements of success[J]. Global Health, 2022, 18(1): 59.
15.	Bongers J, Hillary L, Wieman G. Aligning rulesets: understanding cooperation in the European Union[J]. Polit Res Exchange, 2021, 3(1): 2012086.
16.	Fahy N, Hervey T, Dayan M, et al. Assessing the potential impact on health of the UK's future relationship agreement with the EU: analysis of the negotiating positions[J]. Health Econ Policy Law, 2021, 16(3): 290-307.
17.	Aubrecht P, Essink J, Kovac M, et al. Centralised and decentralised responses to COVID-19: the EU and the USA compared[J]. Utrecht Law Review, 2022, 18(1): 1-18.
18.	Hosseini M. Competition law and ethics of innovation as catalysts for fairness: reimagining the EU's COVID-19 vaccine strategy[J]. J Law Med Ethics, 2025, 53(3): 388-397.
19.	Nhamo G, Chikodzi D, Kunene HP, et al. COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs[J]. Glob Public Health, 2021, 16(3): 319-339.
20.	Boschiero N. COVID-19 vaccines as global common goods: an integrated approach of ethical, economic policy and intellectual property management[J]. Global Jurist, 2022, 22(2): 177-230.
21.	Goniewicz K, Khorram-Manesh A, Hertelendy A J, et al. Current response and management decisions of the European Union to the COVID-19 outbreak: a review[J]. Sustainability, 2020, 12(9): 3838.
22.	Petti A. EU COVID-19 purchase and export mechanism: a framework for EU operational autonomy[J]. Common Market Law Rev, 2022, 59(5): 1-15.
23.	Winkelmann J, Webb E, Williams GA, et al. European countries' responses in ensuring sufficient physical infrastructure and workforce capacity during the first COVID-19 wave[J]. Health Policy, 2022, 126(5): 362-372.
24.	Becker M, Gehring T. Explaining EU integration dynamics in the wake of COVID-19: a domain of application approach[J]. J Euro Public Policy, 2023, 30(2): 334-353.
25.	Fischer T, Mauer N, Tille F. A framework for studying EU health policy through a political determinants of health lens: the case of the European Health Union[J]. J Health Polit Policy Law, 2024, 49(5): 691-720.
26.	Halloran D. Procurement during a public health crisis: the role of the European Union[J]. Irish Stud Inter Affair, 2021, 32(1): 67-81.
27.	European Association of Hospital Pharmacists. Joint procurement-learnings from a pilot of joint procurement of older products[Z]. 2019.
28.	Della Corte FS. The EU vaccines strategy: a missed opportunity for EU public health[J]. Euro J Risk Regul, 2024, 15(2): 333-345.
29.	Arroyo J, Del Giovane C, Mizsei B, et al. The EU vaccines strategy: a mixed bag of achievements and discontent[J]. Euro J Risk Regul, 2024, 15(1): 1-17.
30.	Deters H, Zardo F. The European Commission in COVID-19 vaccine cooperation: leadership vs. coronationalism[J]? J Euro Public Policy, 2023, 30(6): 1051-1071.
31.	Cuschieri S, Agius S, Souness J, et al. The fastest national COVID vaccination in Europe - Malta's strategies[J]. Health Sci Rev (Oxf), 2021, 1: 100001.
32.	Wouters OJ, Forman R, Anderson M, et al. The launch of the EU Health Emergency Preparedness and Response Authority (HERA): improving global pandemic preparedness[J]. Health Policy, 2023, 133: 104844.
33.	Cernuschi T, Malvolti S, Hall S, et al. The quest for more effective vaccine markets - opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic[J]. Vaccine, 2024, 42(Suppl 1): S64-S72.
34.	Vogler S, Van den Ham R, Haasis M A, et al. Together working to improve access to medicines: analysis of cross-country collaborations in Europe[Z]. 2019.
35.	Pagliusi S, Ting CC, Khomvilai S, et al. Quality vaccines for all people: report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand[J]. Vaccine, 2016, 34(31): 3562-3567.
36.	F Etienne C. Expanded program on immunization in the Americas: 40 years[J]. Rev Panam Salud Publica, 2017, 41: e139.
37.	Souza KM, Giron N, Vallini J, et al. Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in Latin American and Caribbean region[J]. J Pharm Policy Pract, 2024, 17(1): 2379045.
38.	Yu Z, Keskinocak P, Orenstein WA, et al. A mixed integer programming model for vaccine pricing within a group purchasing organization[J]. Vaccine, 2024, 42(8): 1892-1898.
39.	Pagliusi S, Leite LC, Datla M, et al. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all[J]. Vaccine, 2013, 31(Suppl 2): B176-B183.
40.	Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products. A systematic review of evidence from low-income and middle-income countries[J]. BMJ Glob Health, 2017, 2(2): e000243.
41.	Oliveira BNL, Oliveira MA. Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America[J]. Cad Saude Publica, 2021, 37(10): e00170920.
42.	de L Horst MM, Soler O. The PAHO Strategic Fund: a mechanism to facilitate access to medicines[J]. Rev Panam Salud Publica, 2010, 27(1): 43-48.
43.	Tambini G, Andrus JK, Fitzsimmons JW, et al. Regional immunization programs as a model for strengthening cooperation among nations[J]. Rev Panam Salud Publica, 2006, 20(1): 54-59.
44.	Skowron R, Grioui N, Ko?win A, et al. HPR103 recent developments in European voluntary cross-border collaborations in joint HTA, drug pricing, procurement, and readiness for EU HTA implementation[J]. Value Health, 2024, 27(12): S295.
45.	Skowron R, Tomaszek E, Famulska A, et al. HPR218 recent advances in voluntary European cross-border collaborations in joint HTA and drug pricing/procurement[J]. Value Health, 2023, 26(12): S291.
46.	Pisarczyk K, Rémuzat C, Skowron R, et al. PNS20 recent advances in the European cross-border collaborations in joint drug procurement landscape[J]. Value Health, 2019, 22: S766.
47.	Stephens T. PNS24 nordic collaborations on procurement and health technology assessment: concepts, components, and outlook[J]. Value Health, 2019, 22: S767.
48.	Zegaoui Y, Butler E, Dawson M. POSA326 cross-border collaboration to support pricing and access for high-cost, high-value therapies: a review of initiatives within Europe[J]. Value Health, 2022, 25(1): S211.
49.	Pisarczyk K, Hajjeji B, Rémuzat C, et al. HT3 description and comparison of European cross-border initiatives on drug procurement[J]. Value Health, 2018, 21: S8-S9.
50.	Achour L, Chachoua L, Dabbous M, et al. European collaboration for innovative high cost medicines[J]. Value Health, 2018, 21: S94.
51.	da Silva JB, García Saisó S, Cornejo S, et al. From hope to reality: how telehealth and strategic procurement are reshaping public health[J]. Rev Panam Salud Publica, 2025, 49: e28.
52.	Rosselli D. High cost drugs in Latin America: access and barriers[J]. Expert Rev Pharmacoecon Outcomes Res, 2023, 23(6): 619-623.
53.	Kane MA, Serrano B, de Sanjosé S, et al. Implementation of human papillomavirus immunization in the developing world[J]. Vaccine, 2012, 30(Suppl 5): F192-F200.
54.	Ropero-álvarez AM, Whittembury A, Kurtis HJ, et al. Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean[J]. Vaccine, 2012, 30(5): 916-921.
55.	Ropero-álvarez AM, El Omeiri N, Kurtis HJ, et al. Influenza vaccination in the Americas: progress and challenges after the 2009 A(H1N1) influenza pandemic[J]. Hum Vaccin Immunother, 2016, 12(8): 2206-2214.
56.	Andrus JK, Sherris J, Fitzsimmons JW, et al. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement[J]. Vaccine, 2008, 26(Suppl 10): K87-K92.
57.	Lal A, Lim C, Almeida G, et al. Minimizing COVID-19 disruption: ensuring the supply of essential health products for health emergencies and routine health services[J]. Lancet Reg Health Am, 2022, 6: 100129.
58.	de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, et al. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience[J]. Pediatr Infect Dis J, 2011, 30(1 Suppl): S61-S66.
59.	Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions[J]. Soc Sci Med, 2012, 75(9): 1572-1580.
60.	Pagliusi S, Dennehy M, Kim H, et al. Vaccines, inspiring innovation in health[J]. Vaccine, 2018, 36(48): 7430-7437.
61.	DeRoeck D, Bawazir SA, Carrasco P, et al. Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program[J]. Int J Health Plann Manage, 2006, 21(1): 23-43.
62.	Vogler S, Haasis MA, van den Ham R, et al. European collaborations on medicine and vaccine procurement[J]. Bull World Health Organ, 2021, 99(10): 715-721.
63.	Gnanakani SPE, Sree PK, Praneetha KPS. A comprehensive review on regulatory requirements of pharmaceutical drug products in CIS and GCC countries[J]. Inter J Pharm Sci Res, 2023, 14(11): 5181-5196.
64.	Khoja TAM, Bawazir SA. Group purchasing of pharmaceuticals and medical supplies by the Gulf Cooperation Council states[J]. East Med Health J, 2005, 11(1/2): 217.
65.	Parmaksiz K, van de Bovenkamp H, Bal R. Does structural form matter. A comparative analysis of pooled procurement mechanisms for health commodities[J]. Global Health, 2023, 19(1): 90.
66.	Kebirungi B, Ocran P, Kamere N, et al. Voluntary information and price sharing database - a scoping review of the pricing and procurement landscape across eight Commonwealth Member States[J]. J Pharm Policy Pract, 2025, 18(1): 2523937.
67.	Muangchana C, Thanormwat Y, Kongsiang A. Workshops advocating ASEAN Vaccine Security and Self-Reliance (AVSSR): a regional initiative[J]. Vaccine, 2019, 37(14): 2034-2041.
68.	Doua J, Ndembi N, Auerbach J, et al. Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges[J]. Vaccine, 2025, 50: 126829.
69.	Changalima IA. Are the COVID-19 pandemic and public procurement ‘strange bedfellows’. An African perspective[J]. Africa Devel, 2023, 48(2): 175-196.
70.	O’Hara GL, Halabi S, Egbokhare O. Equitable vaccine access in light of COVID-19 vaccine procurement strategies in Africa[J]. COVID, 2024, 4(2): 276-288.
71.	Hinestrosa F, Marín J I, Mu?oz Maya O, et al. Update of hepatitis C in Colombia[J]. Current Trop Med Rep, 2018, 5(3): 133-137.
72.	Huff-Rousselle M, Burnett F. Cost containment through pharmaceutical procurement: a Caribbean case study[J]. Int J Health Plann Manage, 1996, 11(2): 135-157.
73.	Kaló Z, Kruja K, Noone D, et al. Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing[J]. BMJ, 2025, 391: e084839.
74.	Mulumba M, Oga J, Koomson N, et al. Decolonizing global health: Africa's pursuit of pharmaceutical sovereignty[J]. BMC Health Serv Res, 2025, 25(1): 1015.
75.	Claessens Z, Beirne G, Decouttere C, et al. Future-proofing European pharmaceutical regulatory and market access practices based on EU learnings from the COVID-19 pandemic: insights from multi-stakeholder interviews[J]. Ther Innov Regul Sci, 2025, 60(1): 105-116.
76.	Edward M, Salum T, Kisoka IA. Health diplomacy for a resilient Africa: addressing shared threats and fostering regional collaboration[J]. Glob Public Health, 2025, 20(1): 2553637.
77.	De Winter SA. Non‐members in a tight spot: how Norway navigated autonomy in EU pandemic management[Z]. Rev Policy Res, 2025.
78.	Hudon PA, Haren MT, Gartner JB, et al. Public healthcare procurement strategies in response to the COVID-19 pandemic: a scoping review[J]. Int J Health Policy Manag, 2025, 14: 8556.
79.	Hay M, Teichert A, Kilz S, et al. Resilience in the vaccine supply chain: learning from the COVID-19 pandemic[J]. Vaccines (Basel), 2025, 13(2): 142.
80.	Alum EU, Ekpang Ii JE, Ekpang PO, et al. Toward an ethical future for orphan drugs: balancing access, affordability, and innovation[J]. J Med Econ, 2025, 28(1): 1869-1886.
81.	McEvoy E. Using pan-European procurements to improve equitable access to Orphan medicines. A Review of the 2025 proposal for a Critical Medicines Act[Z]. 2025.
82.	Perehudoff K. EU's Extraterritorial obligations for global medicine access under the convention on the rights of persons with disability (CPRD)[J]. J Law Med Ethics, 2025, 53(3): 356-364.
83.	胡黌. 歐盟在得失之間調整疫苗戰略[J]. 世界知識, 2021, (5): 44-45.
84.	王森. 新冠肺炎疫情蔓延下歐盟委員會的作用和地位分析[J]. 行政科學論壇, 2021, 8(4): 57-61.

1. Wang LX, Zahur NB. Procurement institutions and essential drug supply in low and middle-income countries[J]. J Health Econ, 2025, 101: 102996.
2. 焦慧霖, 湯少梁, 毛曉艷, 等. 藥品集中帶量采購政策背景下慢性病患者藥品福利感知的變化及對其健康水平的影響研究[J]. 中國衛生經濟, 2025, 44(3): 30-36.
3. 王朝輝, 蔣昌松, 聶曼玲, 等. 國家組織藥品集中采購政策對抗乳腺癌藥品使用的影響研究[J]. 衛生經濟研究, 2025, 42(4): 37-41.
4. Blau J, Hoestlandt C, D Clark A, et al. Strengthening national decision-making on immunization by building capacity for economic evaluation: implementing ProVac in Europe[J]. Vaccine, 2015, 33(Suppl 1): A34-A39.
5. Le Gargasson JB, Breugelmans JG, Mibulumukini B, et al. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC)[J]. Vaccine, 2013, 31(15): 1886-1891.
6. Matiru R, Ryan T. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management[J]. Bull World Health Organ, 2007, 85(5): 348-353.
7. Parmaksiz K, Asingizwe D, Gichohi AK, et al. Towards regional access to medicines: the development of the East African Community pooled procurement mechanism[J]. J Pharm Policy Pract, 2024, 17(1): 2390653.
8. Azzopardi Muscat N. The European added value of health system cooperation to ensure access to innovative medicines and technologies[J]. J Malta College Pharm Pract, 2017, 23: 4-6.
9. Phan D. Access to immunization in middle-income countries: immunization agenda 2030 in depth review[Z]. Immunization Agenda, 2030. 2025.
10. Pagliusi S, Che Y, Dong S. The art of partnerships for vaccines[J]. Vaccine, 2019, 37(40): 5909-5919.
11. Azzopardi-Muscat N, Schroder-B?ck P, Brand H. The European Union Joint procurement agreement for cross-border health threats: what is the potential for this new mechanism of health system collaboration[J]. Health Econ Policy Law, 2017, 12(1): 43-59.
12. 劉晏利, 吳才志, 王浙, 等. JBI范圍綜述執行流程簡介[J]. 中國循證醫學雜志, 2024, 24(8): 986-992.
13. Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review. Guidance for authors when choosing between a systematic or scoping review approach[J]. BMC Med Res Methodol, 2018, 18(1): 143.
14. Parmaksiz K, Pisani E, Bal R, et al. A systematic review of pooled procurement of medicines and vaccines: identifying elements of success[J]. Global Health, 2022, 18(1): 59.
15. Bongers J, Hillary L, Wieman G. Aligning rulesets: understanding cooperation in the European Union[J]. Polit Res Exchange, 2021, 3(1): 2012086.
16. Fahy N, Hervey T, Dayan M, et al. Assessing the potential impact on health of the UK's future relationship agreement with the EU: analysis of the negotiating positions[J]. Health Econ Policy Law, 2021, 16(3): 290-307.
17. Aubrecht P, Essink J, Kovac M, et al. Centralised and decentralised responses to COVID-19: the EU and the USA compared[J]. Utrecht Law Review, 2022, 18(1): 1-18.
18. Hosseini M. Competition law and ethics of innovation as catalysts for fairness: reimagining the EU's COVID-19 vaccine strategy[J]. J Law Med Ethics, 2025, 53(3): 388-397.
19. Nhamo G, Chikodzi D, Kunene HP, et al. COVID-19 vaccines and treatments nationalism: challenges for low-income countries and the attainment of the SDGs[J]. Glob Public Health, 2021, 16(3): 319-339.
20. Boschiero N. COVID-19 vaccines as global common goods: an integrated approach of ethical, economic policy and intellectual property management[J]. Global Jurist, 2022, 22(2): 177-230.
21. Goniewicz K, Khorram-Manesh A, Hertelendy A J, et al. Current response and management decisions of the European Union to the COVID-19 outbreak: a review[J]. Sustainability, 2020, 12(9): 3838.
22. Petti A. EU COVID-19 purchase and export mechanism: a framework for EU operational autonomy[J]. Common Market Law Rev, 2022, 59(5): 1-15.
23. Winkelmann J, Webb E, Williams GA, et al. European countries' responses in ensuring sufficient physical infrastructure and workforce capacity during the first COVID-19 wave[J]. Health Policy, 2022, 126(5): 362-372.
24. Becker M, Gehring T. Explaining EU integration dynamics in the wake of COVID-19: a domain of application approach[J]. J Euro Public Policy, 2023, 30(2): 334-353.
25. Fischer T, Mauer N, Tille F. A framework for studying EU health policy through a political determinants of health lens: the case of the European Health Union[J]. J Health Polit Policy Law, 2024, 49(5): 691-720.
26. Halloran D. Procurement during a public health crisis: the role of the European Union[J]. Irish Stud Inter Affair, 2021, 32(1): 67-81.
27. European Association of Hospital Pharmacists. Joint procurement-learnings from a pilot of joint procurement of older products[Z]. 2019.
28. Della Corte FS. The EU vaccines strategy: a missed opportunity for EU public health[J]. Euro J Risk Regul, 2024, 15(2): 333-345.
29. Arroyo J, Del Giovane C, Mizsei B, et al. The EU vaccines strategy: a mixed bag of achievements and discontent[J]. Euro J Risk Regul, 2024, 15(1): 1-17.
30. Deters H, Zardo F. The European Commission in COVID-19 vaccine cooperation: leadership vs. coronationalism[J]? J Euro Public Policy, 2023, 30(6): 1051-1071.
31. Cuschieri S, Agius S, Souness J, et al. The fastest national COVID vaccination in Europe - Malta's strategies[J]. Health Sci Rev (Oxf), 2021, 1: 100001.
32. Wouters OJ, Forman R, Anderson M, et al. The launch of the EU Health Emergency Preparedness and Response Authority (HERA): improving global pandemic preparedness[J]. Health Policy, 2023, 133: 104844.
33. Cernuschi T, Malvolti S, Hall S, et al. The quest for more effective vaccine markets - opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic[J]. Vaccine, 2024, 42(Suppl 1): S64-S72.
34. Vogler S, Van den Ham R, Haasis M A, et al. Together working to improve access to medicines: analysis of cross-country collaborations in Europe[Z]. 2019.
35. Pagliusi S, Ting CC, Khomvilai S, et al. Quality vaccines for all people: report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand[J]. Vaccine, 2016, 34(31): 3562-3567.
36. F Etienne C. Expanded program on immunization in the Americas: 40 years[J]. Rev Panam Salud Publica, 2017, 41: e139.
37. Souza KM, Giron N, Vallini J, et al. Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in Latin American and Caribbean region[J]. J Pharm Policy Pract, 2024, 17(1): 2379045.
38. Yu Z, Keskinocak P, Orenstein WA, et al. A mixed integer programming model for vaccine pricing within a group purchasing organization[J]. Vaccine, 2024, 42(8): 1892-1898.
39. Pagliusi S, Leite LC, Datla M, et al. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all[J]. Vaccine, 2013, 31(Suppl 2): B176-B183.
40. Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products. A systematic review of evidence from low-income and middle-income countries[J]. BMJ Glob Health, 2017, 2(2): e000243.
41. Oliveira BNL, Oliveira MA. Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America[J]. Cad Saude Publica, 2021, 37(10): e00170920.
42. de L Horst MM, Soler O. The PAHO Strategic Fund: a mechanism to facilitate access to medicines[J]. Rev Panam Salud Publica, 2010, 27(1): 43-48.
43. Tambini G, Andrus JK, Fitzsimmons JW, et al. Regional immunization programs as a model for strengthening cooperation among nations[J]. Rev Panam Salud Publica, 2006, 20(1): 54-59.
44. Skowron R, Grioui N, Ko?win A, et al. HPR103 recent developments in European voluntary cross-border collaborations in joint HTA, drug pricing, procurement, and readiness for EU HTA implementation[J]. Value Health, 2024, 27(12): S295.
45. Skowron R, Tomaszek E, Famulska A, et al. HPR218 recent advances in voluntary European cross-border collaborations in joint HTA and drug pricing/procurement[J]. Value Health, 2023, 26(12): S291.
46. Pisarczyk K, Rémuzat C, Skowron R, et al. PNS20 recent advances in the European cross-border collaborations in joint drug procurement landscape[J]. Value Health, 2019, 22: S766.
47. Stephens T. PNS24 nordic collaborations on procurement and health technology assessment: concepts, components, and outlook[J]. Value Health, 2019, 22: S767.
48. Zegaoui Y, Butler E, Dawson M. POSA326 cross-border collaboration to support pricing and access for high-cost, high-value therapies: a review of initiatives within Europe[J]. Value Health, 2022, 25(1): S211.
49. Pisarczyk K, Hajjeji B, Rémuzat C, et al. HT3 description and comparison of European cross-border initiatives on drug procurement[J]. Value Health, 2018, 21: S8-S9.
50. Achour L, Chachoua L, Dabbous M, et al. European collaboration for innovative high cost medicines[J]. Value Health, 2018, 21: S94.
51. da Silva JB, García Saisó S, Cornejo S, et al. From hope to reality: how telehealth and strategic procurement are reshaping public health[J]. Rev Panam Salud Publica, 2025, 49: e28.
52. Rosselli D. High cost drugs in Latin America: access and barriers[J]. Expert Rev Pharmacoecon Outcomes Res, 2023, 23(6): 619-623.
53. Kane MA, Serrano B, de Sanjosé S, et al. Implementation of human papillomavirus immunization in the developing world[J]. Vaccine, 2012, 30(Suppl 5): F192-F200.
54. Ropero-álvarez AM, Whittembury A, Kurtis HJ, et al. Pandemic influenza vaccination: lessons learned from Latin America and the Caribbean[J]. Vaccine, 2012, 30(5): 916-921.
55. Ropero-álvarez AM, El Omeiri N, Kurtis HJ, et al. Influenza vaccination in the Americas: progress and challenges after the 2009 A(H1N1) influenza pandemic[J]. Hum Vaccin Immunother, 2016, 12(8): 2206-2214.
56. Andrus JK, Sherris J, Fitzsimmons JW, et al. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement[J]. Vaccine, 2008, 26(Suppl 10): K87-K92.
57. Lal A, Lim C, Almeida G, et al. Minimizing COVID-19 disruption: ensuring the supply of essential health products for health emergencies and routine health services[J]. Lancet Reg Health Am, 2022, 6: 100129.
58. de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, et al. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience[J]. Pediatr Infect Dis J, 2011, 30(1 Suppl): S61-S66.
59. Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions[J]. Soc Sci Med, 2012, 75(9): 1572-1580.
60. Pagliusi S, Dennehy M, Kim H, et al. Vaccines, inspiring innovation in health[J]. Vaccine, 2018, 36(48): 7430-7437.
61. DeRoeck D, Bawazir SA, Carrasco P, et al. Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program[J]. Int J Health Plann Manage, 2006, 21(1): 23-43.
62. Vogler S, Haasis MA, van den Ham R, et al. European collaborations on medicine and vaccine procurement[J]. Bull World Health Organ, 2021, 99(10): 715-721.
63. Gnanakani SPE, Sree PK, Praneetha KPS. A comprehensive review on regulatory requirements of pharmaceutical drug products in CIS and GCC countries[J]. Inter J Pharm Sci Res, 2023, 14(11): 5181-5196.
64. Khoja TAM, Bawazir SA. Group purchasing of pharmaceuticals and medical supplies by the Gulf Cooperation Council states[J]. East Med Health J, 2005, 11(1/2): 217.
65. Parmaksiz K, van de Bovenkamp H, Bal R. Does structural form matter. A comparative analysis of pooled procurement mechanisms for health commodities[J]. Global Health, 2023, 19(1): 90.
66. Kebirungi B, Ocran P, Kamere N, et al. Voluntary information and price sharing database - a scoping review of the pricing and procurement landscape across eight Commonwealth Member States[J]. J Pharm Policy Pract, 2025, 18(1): 2523937.
67. Muangchana C, Thanormwat Y, Kongsiang A. Workshops advocating ASEAN Vaccine Security and Self-Reliance (AVSSR): a regional initiative[J]. Vaccine, 2019, 37(14): 2034-2041.
68. Doua J, Ndembi N, Auerbach J, et al. Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges[J]. Vaccine, 2025, 50: 126829.
69. Changalima IA. Are the COVID-19 pandemic and public procurement ‘strange bedfellows’. An African perspective[J]. Africa Devel, 2023, 48(2): 175-196.
70. O’Hara GL, Halabi S, Egbokhare O. Equitable vaccine access in light of COVID-19 vaccine procurement strategies in Africa[J]. COVID, 2024, 4(2): 276-288.
71. Hinestrosa F, Marín J I, Mu?oz Maya O, et al. Update of hepatitis C in Colombia[J]. Current Trop Med Rep, 2018, 5(3): 133-137.
72. Huff-Rousselle M, Burnett F. Cost containment through pharmaceutical procurement: a Caribbean case study[J]. Int J Health Plann Manage, 1996, 11(2): 135-157.
73. Kaló Z, Kruja K, Noone D, et al. Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing[J]. BMJ, 2025, 391: e084839.
74. Mulumba M, Oga J, Koomson N, et al. Decolonizing global health: Africa's pursuit of pharmaceutical sovereignty[J]. BMC Health Serv Res, 2025, 25(1): 1015.
75. Claessens Z, Beirne G, Decouttere C, et al. Future-proofing European pharmaceutical regulatory and market access practices based on EU learnings from the COVID-19 pandemic: insights from multi-stakeholder interviews[J]. Ther Innov Regul Sci, 2025, 60(1): 105-116.
76. Edward M, Salum T, Kisoka IA. Health diplomacy for a resilient Africa: addressing shared threats and fostering regional collaboration[J]. Glob Public Health, 2025, 20(1): 2553637.
77. De Winter SA. Non‐members in a tight spot: how Norway navigated autonomy in EU pandemic management[Z]. Rev Policy Res, 2025.
78. Hudon PA, Haren MT, Gartner JB, et al. Public healthcare procurement strategies in response to the COVID-19 pandemic: a scoping review[J]. Int J Health Policy Manag, 2025, 14: 8556.
79. Hay M, Teichert A, Kilz S, et al. Resilience in the vaccine supply chain: learning from the COVID-19 pandemic[J]. Vaccines (Basel), 2025, 13(2): 142.
80. Alum EU, Ekpang Ii JE, Ekpang PO, et al. Toward an ethical future for orphan drugs: balancing access, affordability, and innovation[J]. J Med Econ, 2025, 28(1): 1869-1886.
81. McEvoy E. Using pan-European procurements to improve equitable access to Orphan medicines. A Review of the 2025 proposal for a Critical Medicines Act[Z]. 2025.
82. Perehudoff K. EU's Extraterritorial obligations for global medicine access under the convention on the rights of persons with disability (CPRD)[J]. J Law Med Ethics, 2025, 53(3): 356-364.
83. 胡黌. 歐盟在得失之間調整疫苗戰略[J]. 世界知識, 2021, (5): 44-45.
84. 王森. 新冠肺炎疫情蔓延下歐盟委員會的作用和地位分析[J]. 行政科學論壇, 2021, 8(4): 57-61.

Chinese Journal of Evidence-Based Medicine

Cross country pharmaceutical regional pooled procurement mechanisms: a scoping review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content